---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Executive summary: Disease burden"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Disease burden. 1 evidence topic quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary/disease-burden"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Hereditary angioedema

<a id="topic-1.1.1-1"></a>

### Summary

Hereditary angioedema (HAE) is estimated to affect 1 in 50,000 people worldwide. A systematic literature review reported a pooled diagnosed annual prevalence of 1.70 per 100,000 (95% confidence interval, 1.58 to 1.83) across HAE types, and a US commercial claims algorithm estimated 2.43 per 100,000 (8694 people) in 2020. In one long-term cohort, symptoms began at a mean age of 11.2 years. Untreated patients may experience attacks every 7 to 14 days on average; abdominal involvement occurs in 70% to 90% of individuals, and laryngeal involvement, which accounts for less than 1% of attacks, occurs at least once in about half of patients. Reported mean or median delays from symptom onset to diagnosis ranged from 3.9 to 26 years.

In one cohort, 70 of 214 patients who had died asphyxiated during a laryngeal attack, 63 of them with undiagnosed HAE; in a second cohort, asphyxiation owing to laryngeal edema caused 39 of 75 deaths (52%). Without a diagnosis, the risk of death with laryngeal edema is estimated at 20% to 25%. In a patient registry, 36.9% of participants with HAE due to C1 inhibitor deficiency reported a family member who died from an HAE attack. Abdominal attacks may lead to “unnecessary surgeries or opiate dependence”, and another cohort reported higher odds of venous thromboembolic disease (odds ratio 4.20) and autoimmune disease (odds ratio 1.65) in HAE, with no increased risk of death (odds ratio 0.69).

In a survey of 260 participants, respondents reported a mean of 11.5 attacks (standard deviation 14.2) in the preceding 6 months, and 137 of 260 (52.7%) had an AE-QoL total score of 39 or higher. In a survey of 457 respondents, 42.5% had depression scores “indicative of depressive symptomatology”, and overall work impairment was 34%. In US commercial claims for 328 patients, mean annualized HAE-related healthcare costs per patient were $165,348 before and $515,333 after starting long-term prophylaxis, driven by prophylaxis pharmacy costs (mean $395,845 per patient per year). A modeled estimate of on-demand treatment alone placed direct costs at $363,795 and indirect costs at $52,576 per patient per year.

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/); [Craig et al. (2026)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema); [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/); [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z); [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/); [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/); [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/); [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/); [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/); [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z); [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
